StockData
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc. (TXMD) stock

TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3026% below fair value
$1.91+0.10 (+5.52%)

Close on Nov 17, 2026Market cap $22.11MP/E –Yield –

TherapeuticsMD operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

TherapeuticsMD's operating income for the twelve months ending Jun 30, 2026 was -$3.95M. For fiscal 2025 it was -$4.39M. The highest annual figure on record is $1.19M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$4.39M–
FY2024Dec 31, 2024-$6.11M–
FY2023Dec 31, 2023-$8.52M-815.6%
FY2022Dec 31, 2022$1.19M–
FY2021Dec 31, 2021-$79.58M–
FY2020Dec 31, 2020-$155.54M–
FY2019Dec 31, 2019-$151.21M–
FY2018Dec 31, 2018-$130.22M–
FY2017Dec 31, 2017-$77.63M–
FY2016Dec 31, 2016-$90.25M–
FY2015Dec 31, 2015-$85.19M–
FY2014Dec 31, 2014-$54.04M–
FY2013Dec 31, 2013-$25.81M–
FY2012Dec 31, 2012-$16.15M–
FY2011Dec 31, 2011-$5.43M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$816.00K–
Q1 FY2026Mar 31, 2026-$723.00K–
Q4 FY2025Dec 31, 2025-$1.55M–
Q3 FY2025Sep 30, 2025-$862.00K–
Q2 FY2025Jun 30, 2025-$695.00K–
Q1 FY2025Mar 31, 2025-$1.28M–
Q4 FY2024Dec 31, 2024-$652.00K–
Q3 FY2024Sep 30, 2024-$1.13M–
Q2 FY2024Jun 30, 2024-$2.79M–
Q1 FY2024Mar 31, 2024-$1.14M–
Q4 FY2023Dec 31, 2023-$1.61M-103.3%
Q3 FY2023Sep 30, 2023-$1.77M–
Q2 FY2023Jun 30, 2023-$2.47M–
Q1 FY2023Mar 31, 2023-$2.67M–
Q4 FY2022Dec 31, 2022$48.44M–
Q3 FY2022Sep 30, 2022-$14.52M–
Q2 FY2022Jun 30, 2022-$14.86M–
Q1 FY2022Mar 31, 2022-$17.88M–
Q4 FY2021Dec 31, 2021-$35.39M–
Q3 FY2021Sep 30, 2021-$39.92M–
Q2 FY2021Jun 30, 2021-$35.18M–
Q1 FY2021Mar 31, 2021-$29.28M–
Q4 FY2020Dec 31, 2020-$34.61M–
Q3 FY2020Sep 30, 2020-$24.97M–
Q2 FY2020Jun 30, 2020-$45.04M–
Q1 FY2020Mar 31, 2020-$50.92M–
Q4 FY2019Dec 31, 2019-$44.39M–
Q3 FY2019Sep 30, 2019-$27.07M–
Q2 FY2019Jun 30, 2019-$41.64M–
Q1 FY2019Mar 31, 2019-$38.11M–
Q4 FY2018Dec 31, 2018-$38.12M–
Q3 FY2018Sep 30, 2018-$34.36M–
Q2 FY2018Jun 30, 2018-$33.02M–
Q1 FY2018Mar 31, 2018-$24.72M–
Q4 FY2017Dec 31, 2017-$21.68M–
Q3 FY2017Sep 30, 2017-$14.83M–
Q2 FY2017Jun 30, 2017-$19.83M–
Q1 FY2017Mar 31, 2017-$21.29M–
Q4 FY2016Dec 31, 2016-$22.94M–
Q3 FY2016Sep 30, 2016-$25.13M–

More TherapeuticsMD figures

See a number that looks wrong?